Samsara BioCapital, LLC reported 23 positions worth $1.21B for the quarter ended Jun 30, 2026, up 17.8% on the prior quarter. It opened 3 new positions, added to 2, trimmed 5 and exited 2. Its largest holding is Scholar Rock Holding Corp at 31.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ALMR Alamar Biosciences, Inc. | +2.48M | – | $67.19M | 5.54% |
| PBLS Parabilis Medicines, Inc. | +556.0K | – | $15.22M | 1.26% |
| ARTV Artiva Biotherapeutics, Inc. | +954.9K | – | $9.26M | 0.764% |
| IVA Inventiva S.A. | +1.12M | +21.6% | $4.23M | 1.97% |
| RANI Rani Therapeutics Holdings, Inc. | +1.87M | +22.0% | $1.42M | 0.651% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ACLX GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT | -60.9K | -100.0% | $6.99M | Exited |
| JBIO Jade Biosciences, Inc. | -232.6K | -24.0% | $5.17M | 1.35% |
| PVLA Palvella Therapeutics, Inc. | -38.4K | -100.0% | $4.79M | Exited |
| UPB Upstream Bio, Inc. | -382.3K | -51.9% | $2.65M | 0.202% |
| XFOR X4 Pharmaceuticals, Inc | -437.0K | -23.8% | $2.04M | 0.538% |
| KLRS Kalaris Therapeutics, Inc. | -66.9K | -0.5% | $272.31K | 4.33% |
| ABVX Abivax S.A. | -1,486 | -2.6% | $198.02K | 0.606% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | Healthcare | 6.90M | $379.37M | 31.3% | 0 | 0.0% | Unchanged | 5.28% |
| 2 | ALMS Alumis Inc. | Healthcare | 6.35M | $178.55M | 14.73% | 0 | 0.0% | Unchanged | 4.97% |
| 3 | MLYS Mineralys Therapeutics, Inc. | Healthcare | 5.87M | $158.40M | 13.07% | 0 | 0.0% | Unchanged | 6.65% |
| 4 | SEPN Septerna, Inc. | Healthcare | 3.15M | $105.46M | 8.7% | 0 | 0.0% | Unchanged | 6.9% |
| 5 | ALMR Alamar Biosciences, Inc. | Healthcare | 2.48M | $67.19M | 5.54% | +2.48M | – | New | 3.57% |
| 6 | NGNE Neurogene Inc. | Healthcare | 1.72M | $54.00M | 4.46% | 0 | 0.0% | Unchanged | 7.61% |
| 7 | KLRS Kalaris Therapeutics, Inc. | Healthcare | 12.88M | $52.43M | 4.33% | -66.9K | -0.5% | Reduced | 54.11% |
| 8 | SGP SpyGlass Pharma, Inc. | Healthcare | 2.11M | $46.97M | 3.88% | 0 | 0.0% | Unchanged | 6.31% |
| 9 | STRO Sutro Biopharma, Inc. | Healthcare | 1.06M | $35.29M | 2.91% | 0 | 0.0% | Unchanged | 6.41% |
| 10 | IVA Inventiva S.A. | Healthcare | 6.31M | $23.87M | 1.97% | +1.12M | +21.6% | Added | 3.38% |
| 11 | JBIO Jade Biosciences, Inc. | Healthcare | 736.2K | $16.36M | 1.35% | -232.6K | -24.0% | Reduced | 1.16% |
| 12 | PBLS Parabilis Medicines, Inc. | Healthcare | 556.0K | $15.22M | 1.26% | +556.0K | – | New | 0.46% |
| 13 | VTVT vTv Therapeutics Inc. | Healthcare | 298.5K | $11.24M | 0.927% | 0 | 0.0% | Unchanged | 7.58% |
| 14 | AQST Aquestive Therapeutics, Inc. | Healthcare | 2.50M | $10.40M | 0.858% | 0 | 0.0% | Unchanged | 1.99% |
| 15 | NKTX Nkarta, Inc. | Healthcare | 3.51M | $9.93M | 0.819% | 0 | 0.0% | Unchanged | 4.71% |
Tip. Select a row to see that position’s full history at Samsara BioCapital.
As of its Q2 2026 13F filing, Samsara BioCapital, LLC’s five largest positions were Scholar Rock Holding Corp (SRRK) at 31.3%, Alumis Inc. (ALMS) at 14.7%, Mineralys Therapeutics, Inc. (MLYS) at 13.1%, Septerna, Inc. (SEPN) at 8.7%, Alamar Biosciences, Inc. (ALMR) at 5.5% of the reported portfolio.
Samsara BioCapital, LLC reported a 13F portfolio worth $1.21B across 23 positions for Q2 2026. That is up 17.8% from the previous quarter.
Its largest purchases by value were Alamar Biosciences, Inc. ($67.19M), Parabilis Medicines, Inc. ($15.22M), Artiva Biotherapeutics, Inc. ($9.26M). It opened 3 new positions.
Its largest sales by value were GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT ($6.99M), Jade Biosciences, Inc. ($5.17M), Palvella Therapeutics, Inc. ($4.79M). It exited 2 positions entirely.
From the Form 13F-HR reports Samsara BioCapital, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.